\n<\/p>\n
Global Nuclear Pharmacy Market 2025-2034 full Research Repot latest version is now available.<\/p>\n
Get Free Access to Demo Report, Excel Pivot and ToC: https:\/\/www.insightaceanalytic.com\/request-sample\/1980<\/a><\/p>\n Latest Drivers Restraint and Opportunities Market Snapshot:<\/p>\n Key factors influencing the global Nuclear Pharmacy market are: The following are the primary obstacles to the Nuclear Pharmacy market’s expansion: Future expansion opportunities for the global Nuclear Pharmacy market include: Key Industry Insights & Findings from the report:<\/p>\n \u0095\tThe industry is expanding as technology advancements allow radiopharmaceuticals to be used to identify and treat malignant tumors. The increasing prevalence of cancer and cardiovascular disorders, advances in radiopharmaceuticals, and the growing usage of nuclear medicine in diagnostic and therapeutic applications are the key drivers of the nuclear medicine market. Market Analysis: Collaborations between pharmaceutical corporations, research universities, and healthcare providers strive to improve product development, streamline distribution routes, and increase patient access to nuclear medical services globally. <\/p>\n List of Prominent Players in the Nuclear Pharmacy Market:<\/p>\n \u0095\tGE HealthCare Expert Knowledge, Just a Click Away: https:\/\/calendly.com\/insightaceanalytic\/30min?month=2025-02<\/a><\/p>\n Recent Developments: Nuclear Pharmacy Market Dynamics: According to the American Heart Association 2022, roughly 19.1 million deaths were related to CVD worldwide in 2020. The age-adjusted mortality rate per 100,000 populations was 239.8, while the age-adjusted prevalence rate was 7354.1 per 100,000. Nuclear medicine plays an important role in illness detection and treatment, and the rising frequency of these disorders is expected to fuel market expansion throughout the forecast period. <\/p>\n Challenges: Technological Complexities and Infrastructure Requirements Establishing and sustaining nuclear pharmacy, cyclotron, and radioisotope manufacturing facilities requires substantial capital commitment, regulatory permissions, and operating skills. <\/p>\n North America Is Expected To Grow With the Highest CAGR during the Forecast Period This infrastructure enables the widespread use of nuclear medicine techniques for diagnostic imaging, treatments, and medical research, resulting in increased demand for radiopharmaceuticals and nuclear pharmacy services. <\/p>\n Unlock Your GTM Strategy: https:\/\/www.insightaceanalytic.com\/customisation\/1980<\/a><\/p>\n Segmentation of Nuclear Pharmacy Market- About Us: Contact us:
\u0095\tIncreasing incidence and prevalence of target conditions
\u0095\tIncreasing Applications in Oncology and Cardiology
\u0095\tRising Prevalence of Chronic Diseases<\/p>\n
\u0095\tTechnological Complexities and Infrastructure Requirements
\u0095\tSupply Chain Disruptions and Radiopharmaceutical Shortages
\u0095\tShort half-life of radiopharmaceuticals<\/p>\n
\u0095\tGrowing Demand for Personalized Medicine
\u0095\tAdvancements in Nuclear Medicine Technologies
\u0095\tTechnological Innovations in Radiopharmaceutical Production <\/p>\n
\u0095\tThe increased government funding for nuclear medical research and development will drive market growth.
\u0095\tA chronic shortage of skilled healthcare professionals impedes the use of nuclear pharmacy technologies.
\u0095\tNorth America is expected to have the largest market share in 2024 due to an increase in surgical procedures and a rise in preference for endovascular devices.<\/p>\n
The market has been influenced by factors such as the rising prevalence of chronic illnesses, advances in nuclear medicine technology, and increased demand for customized medication. Regulatory approvals for new radiopharmaceuticals, expanded applications of nuclear medicine in cancer and neurology, and increased investment in nuclear medicine infrastructure all contribute to the Global Nuclear Pharmacy Market’s growth.<\/p>\n
\u0095\tCardinal Health
\u0095\tCurium
\u0095\tBayer AG
\u0095\tLantheus Holdings, Inc.
\u0095\tBracco Imaging S.p.A.
\u0095\tPharmaLogic Holdings Corp.
\u0095\tEczacibasi-Monrol Nuclear Products
\u0095\tNTP Radioisotopes SOC Ltd
\u0095\tNordion Inc.
\u0095\tNovartis (Advanced Accelerator Application)
\u0095\tNorthStar Medical Radioisotopes
\u0095\tEckert & Ziegler
\u0095\tIsotope JSC
\u0095\tSiemens Healthineers<\/p>\n
\u0095\tIn January 2023, NorthStar Medical Radioisotopes (US) has made significant progress in developing its novel method for producing molybdenum-99 (Mo-99), a crucial medical radioisotope, without using uranium.
\u0095\tIn May 2024, Mauritius launched its new National Cancer Centre in Solferino, marking the completion of nearly 10 years of IAEA support for the country’s nuclear medicine development. The new center is expected to drastically change cancer care for Mauritius patients by consolidating all oncology services, including nuclear medicine, under one roof.
\u0095\tIn January 2023, NorthStar Medical Radioisotopes significantly improved their process to create molybdenum-99 without uranium. This strategic move propels the organization to the forefront of the nuclear medicine market while solving important supply chain challenges.<\/p>\n
Market Drivers: Increasing incidence and prevalence of target conditions
The rising frequency of cancer and cardiovascular illness is a major factor driving market expansion. The majority of instances may be avoided with early identification and treatment; nuclear medicine plays an important role in these areas. <\/p>\n
Technological difficulties and infrastructural needs provide obstacles in the Global Nuclear Pharmacy Market, especially in emerging regions and resource-constrained settings. Radiopharmaceuticals must be produced and delivered using specific infrastructure, equipment, and experience to assure safe handling, synthesis, quality control, and distribution of radioactive medications. <\/p>\n
North America is frequently considered the area controlling the global nuclear pharmacy market. Several reasons contribute to its dominant position in this sector. North America has cutting-edge healthcare infrastructure, with huge networks of hospitals, clinics, and academic medical institutions outfitted with sophisticated imaging technology and nuclear medicine facilities. <\/p>\n
By Type-
\u0095\tDiagnostic Nuclear Medicine
o\tSPECT Radiopharmaceuticals
\uf0a7\tTc-99m
\uf0a7\t1-123
\uf0a7\tTl-201
\uf0a7\tGa-67
\uf0a7\tOther SPECT Isotopes
o\tPET Radiopharmaceuticals
\uf0a7\tF-18
\uf0a7\tRb-82
\uf0a7\tOther PET Isotopes
\u0095\tTherapeutic Nuclear Medicine
o\tAlpha Emitters
\uf0a7\tRa-223
o\tBeta Emitters
\uf0a7\t1-131
\uf0a7\tY-90
\uf0a7\tSm-153
\uf0a7\tLu-177
\uf0a7\tRe-186
\uf0a7\tOther Beta Emitters
\u0095\tBrachytherapy Isotopes
o\t1-125
o\tIr-192
o\tPd-103
o\tCs-131
o\tOther Brachytherapy Isotopes
By Application-
\u0095\tDiagnostic Applications
o\tSPECT Applications
\uf0a7\tCardiology
\uf0a7\tBone Scans
\uf0a7\tThyroid Applications
\uf0a7\tPulmonary Scans
\uf0a7\tOther SPECT Applications
\u0095\tPET Applications
o\tOncology
o\tCardiology
o\tNeurology
o\tOther PET Applications
\u0095\tTherapeutic Applications
o\tThyroid Indications
o\tBone Metastasis
o\tLymphoma
o\tEndocrine Tumors
o\tOther Indications
By Region-
North America-
\u0095\tThe US
\u0095\tCanada
\u0095\tMexico
Europe-
\u0095\tGermany
\u0095\tThe UK
\u0095\tFrance
\u0095\tItaly
\u0095\tSpain
\u0095\tRest of Europe
Asia-Pacific-
\u0095\tChina
\u0095\tJapan
\u0095\tIndia
\u0095\tSouth Korea
\u0095\tSouth East Asia
\u0095\tRest of Asia Pacific
Latin America-
\u0095\tBrazil
\u0095\tArgentina
\u0095\tRest of Latin America
Middle East & Africa-
\u0095\tGCC Countries
\u0095\tSouth Africa
\u0095\tRest of Middle East and Africa<\/p>\n
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.<\/p>\n
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com<\/a>
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com<\/p>\n<\/div>\n